Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Zhejiang Hengkang Pharmaceutical.

    Client Virtual Booth

    ZHEJIANG HENGKANG PHARMACEUTICAL

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    • Ademetionine

    • Ademetionine 1,4-Butanedisulfonate

    • Ademetionine Disulfate Tosylate

    • Amiodarone Hydrochloride

    • Benserazide Hydrochloride

    • Bilastine

    • Deferasirox

    • Eltrombopag

    • Esmolol Hydrochloride

    • Mesalazine

    • Pranlukast Hydrate

    • Riociguat

    • Saxagliptin

    • Vonoprazan Fumarate

    INTERMEDIATES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Hengkang
    Zhejiang Hengkang Pharmaceutical
    China Flag
    Country
    Country
    China
    Address
    Address
    11 Chengen Road, Pubagang Town, Sanmen County, Zhejiang Province, Zip code: 317100
    Telephone
    Telephone
    +86 57683372028
    Client Email
    Email
    marketing@hengkangpharm.cn
    Client Website
    Website
    https://www.hengkangpharm.cn/index_en.html
    Linkedin
    Linkedin
    https://www.linkedin.com/company/zhejiang-hengkang-pharmaceutical-co-ltd/?originalSubdomain=eng
    Twitter
    Twitter
    Contact Info
    Others

    Full View ScreenFull Screen View
    • Deals
    Virtual BoothZhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.

    Zhejiang Hengkang Pharmaceutical Acquires Meiji Pharmaceutical (Shandong) to Enter the Field of Green Synthetic Biology

    Details:

    Through the acquisition, Hengkang entered the field of biosynthesis, improved the commercial production capacity of products in the field of biosynthesis, enriched its product pipeline by adding KD-370, a pentavalent vaccine, approved in Japan.


    Lead Product(s): KD-370

    Therapeutic Area: Infections and Infectious Diseases Product Name: KD-370

    Highest Development Status: ApprovedProduct Type: Vaccine

    Recipient: Meiji Pharmaceutical

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition January 10, 2023

    Hengkang

    TIDES USA

    Booth # 802

    envelop Contact Supplier

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Access Website

    Contact Supplier

    View Presentation

    Hengkang

    TIDES USA

    Booth # 802

    envelop Contact Supplier

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search